Navigation Links
Simeprevir Administered Once Daily as Part of Combination Therapy Demonstrates Sustained Virologic Response in Treatment-Naive and Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
Date:11/2/2013

HCV."

About Hepatitis C
Hepatitis C, a blood-borne infectious disease of the liver and a leading cause of chronic liver disease, is the focus of a rapidly evolving treatment landscape. Approximately 150 million people are infected with hepatitis C worldwide – including approximately 3.2 million people in the United States – and 350,000 people per year die from the disease globally. When left untreated, hepatitis C can cause significant damage to the liver including cirrhosis. Additionally, hepatitis C may increase the risk of developing complications from cirrhosis, which may include liver failure.

About Simeprevir
Simeprevir (TMC435) is an investigational NS3/4A protease inhibitor jointly developed by Janssen R&D Ireland and its affiliated companies and Medivir AB for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease, including all stages of liver fibrosis. Simeprevir works by blocking the viral protease enzyme that enables the hepatitis C virus to replicate in host cells.

Janssen is responsible for the global clinical development of simeprevir and has acquired exclusive, worldwide marketing rights, except for the Nordic countries. Medivir AB will retain marketing rights for simeprevir in these Nordic countries under the marketing authorization held by Janssen-Cilag International NV. Simeprevir was approved on September 27, 2013 in Japan for the treatment of genotype 1 hepatitis C and a Marketing Authorisation Application was submitted to the European Medicines Agency (EMA) by Janssen-Cilag International NV seeking approval of simeprevir for the treatment of genotype 1 or genotype 4 chronic hepatitis C.

Simeprevir is also being studied in several interferon-free regimens using selected combinations of direct-acting antiviral agents with different mechanisms of action. To date, more than 3,700 patients have been tre
'/>"/>

SOURCE Janssen R&D Ireland
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Simeprevir Data in Hepatitis C Patients to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
2. Primary Efficacy and Safety Findings from Phase 3 Study of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
3. U.S. FDA Grants Priority Review to Simeprevir (TMC435) for Combination Treatment of Genotype 1 Chronic Hepatitis C
4. Janssen and Johnson & Johnson to Provide Webcast Presentation of Simeprevir Phase 3 Clinical Data Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
5. Findings from Two Phase 3 Studies of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients
6. Janssen Submits New Drug Application to U.S. FDA for Simeprevir (TMC435) for Combination Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C
7. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
8. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
9. MCOs Shifting Control Over Office-Administered Products from Medical to Pharmacy Benefit, Particularly Affecting Rheumatoid Arthritis Therapies
10. American Journal of Medicine Publishes Hypertension Study Comparing the Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone versus Azilsartan Medoxomil Co-administered with Hydrochlorothiazide
11. Daiichi Sankyos Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014  Australian drug delivery company, Phosphagenics ... has raised A$19.3 million via a placement of A$16.3 ... , the U.S., Asia and ... a share purchase plan (SPP) to be offered to ... made in two tranches. "This capital raising ...
(Date:7/11/2014)... DUBLIN , July 11, 2014 ... the addition of the "Immunoprotein Diagnostic Testing ... at the highest CAGR of 6% and is ... report to their offering. ... for immunoprotein diagnostic testing has been segmented according ...
(Date:7/11/2014)... July 11, 2014 Neurelis, Inc. ("Neurelis") today ... end the option held by Biotie to purchase Neurelis, ... of NRL-1 (intranasal diazepam) for pediatric and adult epilepsy ... the past year, Biotie has advanced the development program ... the pivotal clinical work required for NDA submission to ...
Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
... 13 Allscripts (Nasdaq: MDRX ... results for the three and nine months ended September ... Monday, November 8, 2010. Allscripts management will host a ... and other information at 4:30 PM Eastern Standard Time ...
... Academy of Managed Care Pharmacy (AMCP) 2010 Educational ... Express Scripts (Nasdaq: ESRX ) will ... driving down healthcare costs and providing increased value ... (Logo:   http://photos.prnewswire.com/prnh/20080827/EXPRESSSCRIPTSLOGO ) (Logo:   ...
Cached Medicine Technology:Allscripts to Announce Third Quarter 2010 Results on November 8, 2010 2Allscripts to Announce Third Quarter 2010 Results on November 8, 2010 3Express Scripts Unveils New Opportunities to Drive Down Healthcare Costs; Presents Five Studies at Academy of Managed Care Pharmacy Conference 2Express Scripts Unveils New Opportunities to Drive Down Healthcare Costs; Presents Five Studies at Academy of Managed Care Pharmacy Conference 3
(Date:7/12/2014)... 2014 The "North ... Devices Market by Angioplasty Balloon (Plain/Old, ... OCT), IVC Filter (Retrievable), Endovascular Stent ... and studies the major market drivers, ... and Canada. , Browse 108 market ...
(Date:7/12/2014)... The fastest-growing mobile technology is LTE ... of LTE networks continues to grow due to the ... have increased mobile data traffic, which is a major ... Communications Test and Measurement equipment comply with industry standards, ... Test and Measurement Market is estimated to grown from ...
(Date:7/12/2014)... injuries increase in the summer as people gather around fire ... most vulnerable to these seasonal fire hazards: children. "Young ... by putting their hands on the side of cooking grills," ... Loyola University Medical Center in Maywood, Ill., said in a ... play with fire, you get burned, is true -- ...
(Date:7/12/2014)... Using and carrying around a catheter bag can ... Va., decided that there needed to be an inconspicuous ... of our design," he said. , They then created ... an inconspicuous way to use and carry a catheter’s ... comfort and peace of mind. Producible in design variations, ...
(Date:7/12/2014)... Wright & Schulte LLC has filed a ... a subsidiary of Johnson & Johnson, on behalf of an ... receiving a metal-on-metal DePuy Pinnacle hip replacement and had to ... hip implant. The DePuy hip lawsuit was filed July 7, ... (Case No. 3:14-cv-2427) where DePuy Pinnacle Hip lawsuit litigation ...
Breaking Medicine News(10 mins):Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 2Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 3Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 4Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 5Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 5Health News:Burn Injuries More Common in Summer 2Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 2Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 3Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 4Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 5
... pros, cons to make informed choice about prostate cancer test, ... inability of the prostate specific antigen (PSA) test to distinguish ... a population-wide screening tool, new research claims. , Because of ... overtreatment, according to two reports in the Sept. 25 online ...
... In the future, diagnosing severe personality disorders, evaluating ... analysis of the MAOA genotype may provide more ... according to the Finnish research carried out jointly ... University Central Hospital Psychiatry Centre. "The many ...
... damage more than just your smile? Can failing to attack ... answer to both questions may be yes if you are ... published in the current issue of the Journal of ... Kowolik, B.D.S., Ph.D., professor of periodontics and associate dean for ...
... punishment can affect psychological well-being, , FRIDAY, Sept. 25 (HealthDay ... spanked might lose IQ points. , The good news is ... -- and at least one expert believes that part of ... of favor in the United States and elsewhere. , That,s ...
... ... 1. Practitioner Training: Friday, October 30 , ... Buffalo, NY (PRWEB) September 25, 2009 -- The U.S. Centers ... in the U.S. have an Autism Spectrum Disorder (ASD), which includes autism, Asperger syndrome, ...
... ... Present Completion of New Emergency 911 Center , ... Pittsburgh, PA (PRWEB) September 25, 2009 ... 2009 in San Francisco the firm,s ground-breaking renovation of Washington County,s Emergency 911 ...
Cached Medicine News:Health News:Studies Find PSA Screening Unreliable 2Health News:Studies Find PSA Screening Unreliable 3Health News:New ways to predict violent behavior? 2Health News:Body's immune system response to dental plaque varies by gender and race 2Health News:Spanking May Lower Kids' IQs 2Health News:Spanking May Lower Kids' IQs 3Health News:AutismOne & Autism Canada Present "CHANGING THE COURSE OF AUTISM IN CANADA 2009" University of Toronto 2Health News:AutismOne & Autism Canada Present "CHANGING THE COURSE OF AUTISM IN CANADA 2009" University of Toronto 3Health News:synergIT Presents at VMworld 2009 in San Francisco 2Health News:synergIT Presents at VMworld 2009 in San Francisco 3
For implantation in proximal interphalangeal joints of the lateral toes to correct deformity associated with degenerative or rheumatoid arthritis....
Part of the GraFix® Cruciate Reconstruction System, which is designed to facilitate arthroscopic anterior cruciate ligament reconstructions....
... a new standard in the field of hammertoe ... Made of medical grade silicone, these durable and ... high level of flexibility while maintaining correct toe ... in varying stiffnesses. Lengths are determined by the ...
... Kinetik Great Toe Implant (KGTI) system offers ... of the first MPJ. The implant system ... of motion. , ,The KGTI is the ... metatarsophalangeal joint (MPJ) on the market today. ...
Medicine Products: